WO2020065115A3 - Usos terapéuticos de clústeres cuánticos atómicos - Google Patents

Usos terapéuticos de clústeres cuánticos atómicos Download PDF

Info

Publication number
WO2020065115A3
WO2020065115A3 PCT/ES2019/070637 ES2019070637W WO2020065115A3 WO 2020065115 A3 WO2020065115 A3 WO 2020065115A3 ES 2019070637 W ES2019070637 W ES 2019070637W WO 2020065115 A3 WO2020065115 A3 WO 2020065115A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic uses
atomic quantum
quantum clusters
aqcs
clusters
Prior art date
Application number
PCT/ES2019/070637
Other languages
English (en)
French (fr)
Other versions
WO2020065115A2 (es
Inventor
David BUCETA FERNÁNDEZ
Fernando DOMÍNGUEZ PUENTE
Manuel Arturo López Quintela
Original Assignee
Nanogap Sub-Nm-Powder, S.A.
Universidade De Santiago De Compostela
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112021005775-7A priority Critical patent/BR112021005775A2/pt
Priority to MX2021003566A priority patent/MX2021003566A/es
Priority to KR1020217008140A priority patent/KR20210086606A/ko
Priority to AU2019349780A priority patent/AU2019349780A1/en
Priority to JP2021517797A priority patent/JP2022502450A/ja
Priority to CN201980063142.3A priority patent/CN113179632A/zh
Application filed by Nanogap Sub-Nm-Powder, S.A., Universidade De Santiago De Compostela filed Critical Nanogap Sub-Nm-Powder, S.A.
Priority to EP19794172.7A priority patent/EP3862109A2/en
Priority to CA3111915A priority patent/CA3111915A1/en
Priority to US17/280,051 priority patent/US20220031740A1/en
Publication of WO2020065115A2 publication Critical patent/WO2020065115A2/es
Publication of WO2020065115A3 publication Critical patent/WO2020065115A3/es
Priority to IL281663A priority patent/IL281663A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22C—ALLOYS
    • C22C5/00—Alloys based on noble metals
    • C22C5/06—Alloys based on silver
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C1/00—Electrolytic production, recovery or refining of metals by electrolysis of solutions
    • C25C1/12—Electrolytic production, recovery or refining of metals by electrolysis of solutions of copper
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C1/00—Electrolytic production, recovery or refining of metals by electrolysis of solutions
    • C25C1/20—Electrolytic production, recovery or refining of metals by electrolysis of solutions of noble metals
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C5/00—Electrolytic production, recovery or refining of metal powders or porous metal masses
    • C25C5/02—Electrolytic production, recovery or refining of metal powders or porous metal masses from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2202/00—Treatment under specific physical conditions
    • B22F2202/11—Use of irradiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Nanotechnology (AREA)
  • Electrochemistry (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona una invención relacionada con composiciones y usos terapéuticos de clústeres cuánticos atómicos (AQC), en particular composiciones que consisten esencialmente en AQC que comprenden 5 átomos de metal de transición de valencia cero para su uso en el tratamiento de un trastorno proliferativo celular.
PCT/ES2019/070637 2018-09-26 2019-09-25 Usos terapéuticos de clústeres cuánticos atómicos WO2020065115A2 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
MX2021003566A MX2021003566A (es) 2018-09-26 2019-09-25 Usos terapeuticos de clusteres cuanticos atomicos.
KR1020217008140A KR20210086606A (ko) 2018-09-26 2019-09-25 원자 양자 클러스터의 치료적 용도
AU2019349780A AU2019349780A1 (en) 2018-09-26 2019-09-25 Therapeutic uses of atomic quantum clusters
JP2021517797A JP2022502450A (ja) 2018-09-26 2019-09-25 原子量子クラスターの治療的使用
CN201980063142.3A CN113179632A (zh) 2018-09-26 2019-09-25 原子量子簇的治疗用途
BR112021005775-7A BR112021005775A2 (pt) 2018-09-26 2019-09-25 usos terapêuticos de clusters quânticos atômicos
EP19794172.7A EP3862109A2 (en) 2018-09-26 2019-09-25 Therapeutic uses of atomic quantum clusters
CA3111915A CA3111915A1 (en) 2018-09-26 2019-09-25 Therapeutic uses of atomic quantum clusters
US17/280,051 US20220031740A1 (en) 2018-09-26 2019-09-25 Therapeutic uses of atomic quantum clusters
IL281663A IL281663A (en) 2018-09-26 2021-03-21 Therapeutic uses of atomic quantum clusters

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18196963.5 2018-09-26
EP18196963 2018-09-26
EP18196959 2018-09-26
EP18196959.3 2018-09-26

Publications (2)

Publication Number Publication Date
WO2020065115A2 WO2020065115A2 (es) 2020-04-02
WO2020065115A3 true WO2020065115A3 (es) 2020-05-22

Family

ID=68342935

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2019/070637 WO2020065115A2 (es) 2018-09-26 2019-09-25 Usos terapéuticos de clústeres cuánticos atómicos

Country Status (11)

Country Link
US (1) US20220031740A1 (es)
EP (1) EP3862109A2 (es)
JP (1) JP2022502450A (es)
KR (1) KR20210086606A (es)
CN (1) CN113179632A (es)
AU (1) AU2019349780A1 (es)
BR (1) BR112021005775A2 (es)
CA (1) CA3111915A1 (es)
IL (1) IL281663A (es)
MX (1) MX2021003566A (es)
WO (1) WO2020065115A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1303421C (zh) * 2004-03-24 2007-03-07 南京大学 一种用于有机氯、有机磷农药分析的同步净化提取方法
CN111906328B (zh) * 2020-08-11 2022-10-25 苏州大学 一种177Lu标记的金纳米团簇及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914196A1 (en) * 2005-08-03 2008-04-23 Universidade De Santiago De Compostela Stable atomic quantum clusters, production method thereof and use of same
WO2012059572A1 (en) * 2010-11-05 2012-05-10 Universidade De Santiago De Compostela COMBINATION OF ATOMIC QUANTUM CLUSTERS (AQCs) AND ANTINEOPLASIC DRUGS, AND ITS USE IN THE PREVENTION AND/OR TREATMENT OF CELL PROLIFERATIVE DISORDERS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101113046A (zh) * 2006-07-25 2008-01-30 安正五 纳米胶体银水的制备方法
ES2319064B1 (es) * 2007-10-05 2010-02-15 Universidad De Santiago De Compostela Uso de clusteres cuanticos atomicos (aqcs) como antimicrobianos y biocidas.
CN101486733B (zh) * 2009-03-09 2011-05-25 华南师范大学 含氧桥双核钼原子簇化合物及其制备方法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914196A1 (en) * 2005-08-03 2008-04-23 Universidade De Santiago De Compostela Stable atomic quantum clusters, production method thereof and use of same
WO2012059572A1 (en) * 2010-11-05 2012-05-10 Universidade De Santiago De Compostela COMBINATION OF ATOMIC QUANTUM CLUSTERS (AQCs) AND ANTINEOPLASIC DRUGS, AND ITS USE IN THE PREVENTION AND/OR TREATMENT OF CELL PROLIFERATIVE DISORDERS
EP2457572A1 (en) * 2010-11-05 2012-05-30 Universidade De Santiago De Compostela Use of atomic quantum clusters (aqcs) in the prevention of cell proliferative disorders, viral infections and autoimmune diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEATRIZ SANTIAGO GONZÁLEZ ET AL: "Single step electrochemical synthesis of hydrophilic/hydrophobic Ag5 and Ag6 blue luminescent clusters", NANOSCALE, vol. 4, no. 24, 1 January 2012 (2012-01-01), United Kingdom, pages 7632, XP055536107, ISSN: 2040-3364, DOI: 10.1039/c2nr31994b *
VANESA PORTO ET AL: "Silver Atomic Quantum Clusters of Three Atoms for Cancer Therapy: Targeting Chromatin Compaction to Increase the Therapeutic Index of Chemotherapy", ADVANCED MATERIALS, vol. 30, no. 33, 1 August 2018 (2018-08-01), DE, pages 1801317, XP055535054, ISSN: 0935-9648, DOI: 10.1002/adma.201801317 *

Also Published As

Publication number Publication date
JP2022502450A (ja) 2022-01-11
BR112021005775A2 (pt) 2021-06-29
AU2019349780A1 (en) 2021-03-25
IL281663A (en) 2021-05-31
MX2021003566A (es) 2021-08-16
US20220031740A1 (en) 2022-02-03
WO2020065115A2 (es) 2020-04-02
CA3111915A1 (en) 2020-04-02
EP3862109A2 (en) 2021-08-11
CN113179632A (zh) 2021-07-27
KR20210086606A (ko) 2021-07-08

Similar Documents

Publication Publication Date Title
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
SG10201811454WA (en) Materials and methods for controlling infections
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
WO2017178892A3 (en) Selenium disulfide compositions for use in treating meibomian gland dysfunction
SG10201808055QA (en) Compositions and methods for reducing major adverse cardiovascular events
NZ732241A (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
EP4295909A3 (en) Carbidopa and l-dopa prodrugs and methods of use
WO2020065115A3 (es) Usos terapéuticos de clústeres cuánticos atómicos
MX2022003037A (es) Compuestos antibacterianos.
EP3886868A4 (en) COPPER ANOCLUSTERS, COMPOSITION CONTAINING THIS AND TREATMENT OF MULTIPLE SCLEROSIS
WO2018178243A3 (en) Dihydrotetrabenazine for use in the treatment a movement disorder
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX368853B (es) Composiciones y métodos tópicos para el tratamiento de heridas.
CN113038946A8 (zh) 用生物素组合物治疗自闭症和自闭症谱系障碍
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
IL287704A (en) Use of cannabidiol in the treatment of multiple sclerosis complex
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
MX2021006488A (es) Composiciones para mejorar la funcion sexual.
WO2019075216A8 (en) Plectin-1 binding antibodies and uses thereof
WO2018074862A3 (ko) Tha를 유효성분으로 포함하는 유방암 치료용 약학적 조성물
WO2021041324A3 (en) Compositions and methods for the treatment of pathological pain and itch

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19794172

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3111915

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019349780

Country of ref document: AU

Date of ref document: 20190925

Kind code of ref document: A

Ref document number: 2021517797

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021005775

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019794172

Country of ref document: EP

Effective date: 20210426

ENP Entry into the national phase

Ref document number: 112021005775

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210325